Search Results - "EVERLY, Matthew J"

Prevalence and Impact of De Novo Donor‐Specific Antibodies During a Multicenter Immunosuppression Withdrawal Trial in Adult Liver Transplant Recipients by Jucaud, Vadim, Shaked, Abraham, DesMarais, Michele, Sayre, Peter, Feng, Sandy, Levitsky, Josh, Everly, Matthew J.

“…The development of human leukocyte antigen (HLA) donor‐specific antibody/antibodies (DSA) is not well described in liver transplant (LT) patients undergoing…”
Get full text

Incidence and impact of de novo donor-specific alloantibody in primary renal allografts by Everly, Matthew J, Rebellato, Lorita M, Haisch, Carl E, Ozawa, Miyuki, Parker, Karen, Briley, Kimberly P, Catrou, Paul G, Bolin, Paul, Kendrick, William T, Kendrick, Scott A, Harland, Robert C, Terasaki, Paul I

“…To date, limited information is available describing the incidence and impact of de novo donor-specific anti-human leukocyte antigen (HLA) antibodies (dnDSA)…”
Get full text

Pediatric intestinal transplantation: Analysis of the intestinal transplant registry by Raghu, Vikram K., Beaumont, Jennifer L., Everly, Matthew J., Venick, Robert S., Lacaille, Florence, Mazariegos, George V.

“…The ITR serves as an international database for centers around the world to contribute to current knowledge about intestinal transplant outcomes. Led by the…”
Get full text

Bortezomib Provides Effective Therapy for Antibody-and Cell-Mediated Acute Rejection by EVERLY, Matthew J, EVERLY, Jason J, CARDI, Michael, WADIH, George, TEVAR, Amit, WOODIE, E. Steve, SUSSKIND, Brian, BRAILEY, Paul, ARENA, Lois J, ALLOWAY, Rita R, ROY-CHAUDHURY, Prabir, GOVIL, Amit, MOGILISHETTY, Gautham, RIKE, Adele H

“…Current antihumoral therapies in transplantation and autoimmune disease do not target the mature antibody-producing plasma cell. Bortezomib is a first in class…”
Get full text

HLA-Specific Antibodies Developed in the First Year Posttransplant are Predictive of Chronic Rejection and Renal Graft Loss by LEE, Po-Chang, LAN ZHU, TERASAKI, Paul I, EVERLY, Matthew J

“…Evidence shows posttransplant antibodies lead to renal allograft failure, but does the time elapsed between transplantation and antibody development impact…”
Get full text

Alloantibody and Autoantibody Monitoring Predicts Islet Transplantation Outcome in Human Type 1 Diabetes by PIEMONTI, Lorenzo, EVERLY, Matthew J, LAMPASONA, Vito, DE ARIAS, Alejandro Espadas, SCALAMOGNA, Mario, BOSI, Emanuele, BONIFACIO, Ezio, SECCHI, Antonio, TERASAKI, Paul I, MAFFI, Paola, SCAVINI, Marina, POLI, Francesca, NANO, Rita, CARDILLO, Massimo, MELZI, Raffaella, MERCALLI, Alessia, SORDI, Valeria

“…Long-term clinical outcome of islet transplantation is hampered by the rejection and recurrence of autoimmunity. Accurate monitoring may allow for early…”
Get full text

Impact of IgM and IgG3 Anti-HLA Alloantibodies in Primary Renal Allograft Recipients by Everly, Matthew J, Rebellato, Lorita M, Haisch, Carl E, Briley, Kimberly P, Bolin, Paul, Kendrick, William T, Kendrick, Scott A, Morgan, Claire, Maldonado, Angela Q, Harland, Robert C, Terasaki, Paul I

“…BACKGROUNDWith standard IgG donor-specific anti-HLA antibody (DSA) testing, it is unclear which immunoglobulin-G (IgG) DSA positive patients will fail. We…”
Get full text

Abrogation of Anti-HLA Antibodies via Proteasome Inhibition by TRIVEDI, Hargovind L, TERASAKI, Paul I, KHEMCHANDANI, Sajani I, DAVE, Shruti D, FEROZ, Aziz, EVERLY, Matthew J, VANIKAR, Aruna V, SHANKAR, Vangipurapu, TRIVEDI, Varsha B, KANEKU, Hugo, IDICA, Adam K, MODI, Pranjal R

“…Current treatments for autoantibody-mediated diseases (i.e., systemic lupus erythematosus) and alloantibodies (in transplant) are minimally effective. Although…”
Get full text

The state of therapy for removal of alloantibody producing plasma cells in transplantation by Everly, Matthew J, Terasaki, Paul I

“…Highlights ► DSA is a major cause of allograft loss. ► The long-lived plasma cells are the major source of donor specific alloantibody production. ► Proteasome…”
Get full text

Using Donor-Specific Antibodies to Monitor the Need for Immunosuppression by HOSHINO, Junichi, KANEKU, Hugo, EVERLY, Matthew J, GREENLAND, Sander, TERASAKI, Paul I

“…Experience with tolerance protocols has shown that none is perfect and that each escape from tolerance must be identified early to prevent graft failure. In…”
Get full text

Protective Immunity Remains Intact After Antibody Removal by Means of Proteasome Inhibition by EVERLY, Matthew J, TERASAKI, Paul I, HOPFIELD, Judy, TRIVEDI, Hargovind L, KANEKU, Hugo

“…Proteasome inhibition abrogates donor-specific anti-human leukocyte antigen (HLA) antibody (DSA) in patients posttransplant. However, its effects on protective…”
Get full text

Impact of Tocilizumab (Anti–IL-6R) Treatment on Immunoglobulins and Anti-HLA Antibodies in Kidney Transplant Patients With Chronic Antibody-mediated Rejection by Shin, Bong-Ha, Everly, Matthew J., Zhang, Hao, Choi, J., Vo, Ashley, Zhang, Xiaohai, Huang, Edmund, Jordan, Stanley C., Toyoda, Mieko

“…BACKGROUND.Chronic antibody-mediated rejection (cAMR) results in the majority of renal allograft losses. Currently, there are no approved therapies. We…”
Get full text

Monitoring and treating posttransplant human leukocyte antigen antibodies by Everly, Matthew J, Terasaki, Paul I

“…Abstract The important role of preformed human leukocyte antigen (HLA) antibodies in the outcome of organ transplants has been well demonstrated for the past…”
Get full text

Trajectories of health‐related quality of life among renal transplant patients associated with graft failure and symptom distress: Analysis of the BENEFIT and BENEFIT‐EXT trials by Purnajo, Intan, Beaumont, Jennifer L., Polinsky, Martin, Alemao, Evo, Everly, Matthew J.

“…Understanding the correlation between transplant symptoms, health‐related quality of life (HRQoL), and graft outcomes is needed to support patient‐focused drug…”
Get full text

Personalized prediction of delayed graft function for recipients of deceased donor kidney transplants with machine learning by Kawakita, Satoru, Beaumont, Jennifer L., Jucaud, Vadim, Everly, Matthew J.

“…Machine learning (ML) has shown its potential to improve patient care over the last decade. In organ transplantation, delayed graft function (DGF) remains a…”
Get full text

Antibiotic pretreatment alleviates liver transplant damage in mice and humans by Nakamura, Kojiro, Kageyama, Shoichi, Ito, Takahiro, Hirao, Hirofumi, Kadono, Kentaro, Aziz, Antony, Dery, Kenneth J, Everly, Matthew J, Taura, Kojiro, Uemoto, Shinji, Farmer, Douglas G, Kaldas, Fady M, Busuttil, Ronald W, Kupiec-Weglinski, Jerzy W

“…Although modifications of gut microbiota with antibiotics (Abx) influence mouse skin and cardiac allografts, its role in orthotopic liver transplantation (OLT)…”
Get full text

Donor-specific Antibodies, Immunoglobulin-free Light Chains, and BAFF Levels in Relation to Risk of Late-onset PTLD in Liver Recipients by Engels, Eric A., Jennings, Linda W., Everly, Matthew J., Landgren, Ola, Murata, Kazunori, Yanik, Elizabeth L., Pfeiffer, Ruth M., Onaca, Nicholas, Klintmalm, Goran B.

“…Posttransplant lymphoproliferative disorder (PTLD) is a neoplastic complication of transplantation, with early cases largely due to immunosuppression and…”
Get full text

Comparison of de novo IgM and IgG anti‐HLA DSAs between belatacept‐ and calcineurin‐treated patients: An analysis of the BENEFIT and BENEFIT‐EXT trial cohorts by Everly, Matthew J., Roberts, Mustimbo, Townsend, Robert, Bray, Robert A., Gebel, Howard M.

“…Preventing conversion of donor‐specific anti‐HLA antibodies (DSAs) from an IgM‐to‐IgG could a way to prevent chronic rejection. We evaluated whether…”
Get full text

Role of proteasome inhibition in sensitized transplant candidates by Everly, Matthew J, Everly, Jason J, Terasaki, Paul I

“…Objective To review this efficacy and safety of bortezomib, a proteasome inhibitor, in the setting of the sensitized transplant candidate. Data sources The…”
Get full text

Prevalence and Clinical Impact of Donor-Specific Alloantibody Among Intestinal Transplant Recipients by Cheng, Elaine Y, Everly, Matthew J, Kaneku, Hugo, Banuelos, Nubia, Wozniak, Laura J, Venick, Robert S, Marcus, Elizabeth A, McDiarmid, Suzanne V, Busuttil, Ronald W, Terasaki, Paul I, Farmer, Douglas G

“…BACKGROUNDRejection remains the leading cause of allograft loss, and a major barrier to improving long-term outcomes after intestinal transplantation. Our aim…”
Get full text